Factors Associated with the Serum Myostatin Level in Patients Undergoing Peritoneal Dialysis

Potential Effects of Skeletal Muscle Mass and Vitamin D Receptor Activator Use

Shunsuke Yamada, Kazuhiko Tsuruya, Hisako Yoshida, Masanori Tokumoto, Kenji Ueki, Hiroaki Ooboshi, Takanari Kitazono

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

Myostatin is a member of the transforming growth factor-β family, which regulates synthesis and degradation of skeletal muscle proteins and is associated with the development of sarcopenia. It is up-regulated in the skeletal muscle of chronic kidney disease patients and is considered to be involved in the development of uremic sarcopenia. However, serum myostatin levels have rarely been determined, and the relationship between serum myostatin levels with clinical and metabolic factors remains unknown. This cross-sectional study investigated the association between serum myostatin level and clinical factors in 69 outpatients undergoing peritoneal dialysis. Serum myostatin level was determined by commercially available enzyme-linked immunosorbent assay (ELISA). Univariable and multivariable analysis were conducted to determine factors associated with serum myostatin levels. The factors included age, sex, diabetes mellitus, dialysis history, body mass index, residual kidney function, peritoneal dialysate volume, serum biochemistries, and the use of vitamin D receptor activators (VDRAs). Mean serum myostatin level was 7.59 ± 3.37 ng/mL. There was no association between serum myostatin level and residual kidney function. Serum myostatin levels were significantly and positively associated with lean body mass measured by the creatinine kinetic method and negatively associated with the use of VDRAs after adjustment for potential confounding factors. Our study indicated that serum myostatin levels are associated with skeletal muscle mass and are lower in patients treated with VDRAs. Further studies are necessary to determine the significance of measuring serum myostatin level in patients undergoing peritoneal dialysis.

元の言語英語
ページ(範囲)13-22
ページ数10
ジャーナルCalcified Tissue International
99
発行部数1
DOI
出版物ステータス出版済み - 7 1 2016

Fingerprint

Myostatin
Calcitriol Receptors
Peritoneal Dialysis
Skeletal Muscle
Serum
Sarcopenia
Kidney
Muscle Proteins
Age Factors
Dialysis Solutions
Transforming Growth Factors
Chronic Renal Insufficiency
Biochemistry
Dialysis
Creatinine
Diabetes Mellitus
Body Mass Index
Outpatients

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology

これを引用

Factors Associated with the Serum Myostatin Level in Patients Undergoing Peritoneal Dialysis : Potential Effects of Skeletal Muscle Mass and Vitamin D Receptor Activator Use. / Yamada, Shunsuke; Tsuruya, Kazuhiko; Yoshida, Hisako; Tokumoto, Masanori; Ueki, Kenji; Ooboshi, Hiroaki; Kitazono, Takanari.

:: Calcified Tissue International, 巻 99, 番号 1, 01.07.2016, p. 13-22.

研究成果: ジャーナルへの寄稿記事

@article{8eef79e69b704d2e99859098722db343,
title = "Factors Associated with the Serum Myostatin Level in Patients Undergoing Peritoneal Dialysis: Potential Effects of Skeletal Muscle Mass and Vitamin D Receptor Activator Use",
abstract = "Myostatin is a member of the transforming growth factor-β family, which regulates synthesis and degradation of skeletal muscle proteins and is associated with the development of sarcopenia. It is up-regulated in the skeletal muscle of chronic kidney disease patients and is considered to be involved in the development of uremic sarcopenia. However, serum myostatin levels have rarely been determined, and the relationship between serum myostatin levels with clinical and metabolic factors remains unknown. This cross-sectional study investigated the association between serum myostatin level and clinical factors in 69 outpatients undergoing peritoneal dialysis. Serum myostatin level was determined by commercially available enzyme-linked immunosorbent assay (ELISA). Univariable and multivariable analysis were conducted to determine factors associated with serum myostatin levels. The factors included age, sex, diabetes mellitus, dialysis history, body mass index, residual kidney function, peritoneal dialysate volume, serum biochemistries, and the use of vitamin D receptor activators (VDRAs). Mean serum myostatin level was 7.59 ± 3.37 ng/mL. There was no association between serum myostatin level and residual kidney function. Serum myostatin levels were significantly and positively associated with lean body mass measured by the creatinine kinetic method and negatively associated with the use of VDRAs after adjustment for potential confounding factors. Our study indicated that serum myostatin levels are associated with skeletal muscle mass and are lower in patients treated with VDRAs. Further studies are necessary to determine the significance of measuring serum myostatin level in patients undergoing peritoneal dialysis.",
author = "Shunsuke Yamada and Kazuhiko Tsuruya and Hisako Yoshida and Masanori Tokumoto and Kenji Ueki and Hiroaki Ooboshi and Takanari Kitazono",
year = "2016",
month = "7",
day = "1",
doi = "10.1007/s00223-016-0118-6",
language = "English",
volume = "99",
pages = "13--22",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Factors Associated with the Serum Myostatin Level in Patients Undergoing Peritoneal Dialysis

T2 - Potential Effects of Skeletal Muscle Mass and Vitamin D Receptor Activator Use

AU - Yamada, Shunsuke

AU - Tsuruya, Kazuhiko

AU - Yoshida, Hisako

AU - Tokumoto, Masanori

AU - Ueki, Kenji

AU - Ooboshi, Hiroaki

AU - Kitazono, Takanari

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Myostatin is a member of the transforming growth factor-β family, which regulates synthesis and degradation of skeletal muscle proteins and is associated with the development of sarcopenia. It is up-regulated in the skeletal muscle of chronic kidney disease patients and is considered to be involved in the development of uremic sarcopenia. However, serum myostatin levels have rarely been determined, and the relationship between serum myostatin levels with clinical and metabolic factors remains unknown. This cross-sectional study investigated the association between serum myostatin level and clinical factors in 69 outpatients undergoing peritoneal dialysis. Serum myostatin level was determined by commercially available enzyme-linked immunosorbent assay (ELISA). Univariable and multivariable analysis were conducted to determine factors associated with serum myostatin levels. The factors included age, sex, diabetes mellitus, dialysis history, body mass index, residual kidney function, peritoneal dialysate volume, serum biochemistries, and the use of vitamin D receptor activators (VDRAs). Mean serum myostatin level was 7.59 ± 3.37 ng/mL. There was no association between serum myostatin level and residual kidney function. Serum myostatin levels were significantly and positively associated with lean body mass measured by the creatinine kinetic method and negatively associated with the use of VDRAs after adjustment for potential confounding factors. Our study indicated that serum myostatin levels are associated with skeletal muscle mass and are lower in patients treated with VDRAs. Further studies are necessary to determine the significance of measuring serum myostatin level in patients undergoing peritoneal dialysis.

AB - Myostatin is a member of the transforming growth factor-β family, which regulates synthesis and degradation of skeletal muscle proteins and is associated with the development of sarcopenia. It is up-regulated in the skeletal muscle of chronic kidney disease patients and is considered to be involved in the development of uremic sarcopenia. However, serum myostatin levels have rarely been determined, and the relationship between serum myostatin levels with clinical and metabolic factors remains unknown. This cross-sectional study investigated the association between serum myostatin level and clinical factors in 69 outpatients undergoing peritoneal dialysis. Serum myostatin level was determined by commercially available enzyme-linked immunosorbent assay (ELISA). Univariable and multivariable analysis were conducted to determine factors associated with serum myostatin levels. The factors included age, sex, diabetes mellitus, dialysis history, body mass index, residual kidney function, peritoneal dialysate volume, serum biochemistries, and the use of vitamin D receptor activators (VDRAs). Mean serum myostatin level was 7.59 ± 3.37 ng/mL. There was no association between serum myostatin level and residual kidney function. Serum myostatin levels were significantly and positively associated with lean body mass measured by the creatinine kinetic method and negatively associated with the use of VDRAs after adjustment for potential confounding factors. Our study indicated that serum myostatin levels are associated with skeletal muscle mass and are lower in patients treated with VDRAs. Further studies are necessary to determine the significance of measuring serum myostatin level in patients undergoing peritoneal dialysis.

UR - http://www.scopus.com/inward/record.url?scp=84971357085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971357085&partnerID=8YFLogxK

U2 - 10.1007/s00223-016-0118-6

DO - 10.1007/s00223-016-0118-6

M3 - Article

VL - 99

SP - 13

EP - 22

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 1

ER -